Beam Therapeutics upgraded by JP Morgan with a new price target

1/29/24 7:05:19 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

JP Morgan upgraded Beam Therapeutics from Neutral to Overweight and set a new price target of $40.00 from $38.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BEAM

Date	Price Target	Rating	Analyst
3/28/2025	$42.00	Neutral → Buy	BofA Securities
3/10/2025	$40.00	Sector Perform → Sector Outperform	Scotiabank
1/29/2025		Neutral → Overweight	Cantor Fitzgerald
11/6/2024	$27.00 → $39.00	Market Perform → Outperform	Leerink Partners
10/16/2024		Sector Outperform	Scotiabank
7/23/2024	$80.00	Buy	H.C. Wainwright
1/29/2024	$38.00 → $40.00	Neutral → Overweight	JP Morgan
12/15/2023	$35.00	Buy → Neutral	BofA Securities